Research progress on renoprotective mechanisms and clinical applications of GLP-1 receptor agonists in non-diabetic chronic kidney disease
LI Zehui
SHEN Qing
Abstract：Non-diabetic chronic kidney disease(CKD)shares similar risks of end-stage renal disease(ESRD)and a higher incidence of cardiovascular complications with diabetic kidney disease,yet current standard clinical regimens show suboptimal therapeutic effects.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs)exert renoprotective effects in non-diabetic CKD through both direct and indirect mechanisms,involving metabolic regulation,anti-inflammatory responses,and anti-fibrotic processes.Clinical studies indicate that GLP-1 RAs reduce proteinuria levels and maintain renal function stability in patients with non-diabetic CKD,and the therapeutic effects are particularly significant in patients with obesity-or hypertension-related non-diabetic CKD.Future research should further explore the combination strategies of GLP-1 RAs with existing sodium-glucose cotransporter-2(SGLT2)inhibitors,and investigate biomarker-based personalized applica-tion schemes to improve the prognosis of patients with non-diabetic CKD.
Keywords：glucagon-like peptide-1 receptor agonistsnon-diabetic chronic kidney diseasekidney protectionproteinuriacombination therapy
Publication Date：2025-12-25
Online Publishing Date：2026-01-12(First online date of this platform, not the publication date of the document)
Pages：4( 122-125 )